The scientific profile of Kyverna Therapeutics combines autoimmune cell therapy with B-cell depletion through CAR-T therapy, distinguishing the company from noncellular therapeutic developers. The company links immune system reset for autoimmunity with systemic lupus erythematosus cell therapy; systemic sclerosis cellular therapy shows how cell identity or engineering is translated into a therapeutic function. Specific cell types, genetic modifications and therapeutic products remain distinct tags; the cellular strategy of Kyverna Therapeutics also includes autologous immune cell manufacturing.
A single dose of miv-cel from Kyverna Therapeutics kept patients with stiff person syndrome and generalized myasthenia gravis in drug-free remission for a year, according to new trial results.
We use cookies to operate the website and understand site usage and improve your experience
